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The purpose of this study was to evaluate changes in biomarker and syno-
vial parameters following autologous osteochondral transplantation (AOT) in the 
equine stifle joint, to test the hypothesis whether synovial parameters would show 
significant differences at selected time points following the surgery (at days 3, 14, 
60 and 180) compared to baseline level (at day 0). Surgical intervention was per-
formed in both stifles of nine horses (n = 18). The joints were randomly assigned 
to operated and sham-operated groups. Grafts 8.5 mm in diameter were harvested 
from the femoropatellar (FP) joint under arthroscopic control and the medial 
femorotibial (MFT) joints had AOT using mosaicplasty (MP) instrumentation, 
while the sham FP and sham MFT joints underwent arthroscopy and mini-
arthrotomy without transplantation, respectively. Synovial fluid (SF) parameters 
were evaluated at days 4, 14, 60 and 180. Data were analysed by two-way re-
peated-measures analysis of variance (ANOVA), and P < 0.05 was considered 
significant. During the first 10–14 days after surgery, lameness of degree 2–3/5 
[American Association of Equine Practitioners (AAEP) scores] was present, which 
disappeared after 60 days. Joints with transplantation showed significant increases 
in synovial white blood cell count (WBC), total protein (TP), substance P, C1,2C 
and CS846 epitope concentration at day 3 compared to baseline and sham-
operated joints (P < 0.05). These parameters returned to the baseline values by 
two months after surgery and remained within normal levels at 6 months post-
operatively.  
Key words: Stifle, horse, joint, biomarker, mosaicplasty, synovium, carti-
lage  
Lesions on the weight-bearing surface frequently occur in the equine me-
dial femoral condyle (MFC) and may cause lameness. Such lesions are often 
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caused by trauma. The most frequent lesions involve fissures, fibrillation or ul-
ceration of the surface or subchondral bone cysts (SBC) at that location. In both 
human and equine patients, focal cartilaginous lesions can originate from chon-
dropathy or chondral trauma and are difficult to treat and manage, especially on 
weight-bearing joint surfaces (Hangody et al., 2010; Nixon et al., 2011). When 
such lesions are left untreated, the biomechanical protective function of cartilage 
declines, subsequently leading to a loss of joint function (Buckwalter and Man-
kin, 1998) and predisposing the joint to the development of osteoarthritis (OA) 
(Malda et al., 2012). Depending on the location and extent of lesions, surgical 
treatment is often recommended, especially in cases that are refractory to conser-
vative management. 
Autologous osteochondral transplantation (AOT) using the mosaicplasty 
(MP) method has become one of the worldwide accepted techniques for resurfac-
ing damaged joint surfaces of up to 1–4 cm2 even in elite athletes (Hangody et 
al., 2010). Equine clinical studies in the stifle (Bodó et al., 2000; Bodó et al., 
2004) and hock (Janicek et al., 2010) as well as experimental studies (Bodó et 
al., 2014) using the MP method have demonstrated favourable outcomes with 
this method. 
Although the use of biomarkers to detect disease is a relatively new tech-
nique, it has already been demonstrated to provide reliable results at an early 
stage of a disorder. Biomarkers have been employed to date in experimental 
equine studies (Billinghurst et al., 1997; Frisbie et al., 1999; Laverty et al., 2000; 
Celeste et al., 2005) and are a promising tool for diagnostic purposes (de Grauw 
et al., 2006). As the early detection of a joint disease is crucial for the outcome of 
treatment, the use of biomarkers is a great tool (Van Weeren and Firth, 2008). A 
biomarker is a parameter that can be measured objectively and evaluated as an 
indicator of normal physiological or pathological functions and processes (Bio-
markers Definitions Working Group, 2001). Direct markers are indicators of in-
creased or abnormal anabolic or catabolic activity related to constituents of the 
extracellular matrix (ECM) of musculoskeletal tissues. Indirect markers, however, 
are not components of the ECM but may act on ECM metabolism and, therefore, 
have an indirect influence on tissue integrity. The best candidates for biomarkers 
in osteoarthritis are most likely to be structural molecules or fragments linked to 
cartilage, bone or synovium and may be specific to one type of joint tissue or 
common to them all. They may represent tissue degradation or tissue synthesis 
and may be measured in synovial fluid, blood or urine (Lotz et al., 2013).  
The chondroitin sulphate (CS) 846 (CS846) epitope is an indicator of large 
or fetal-like aggrecan synthesis. This epitope is only present on the largest aggre-
can molecules and was originally identified in human fetal cartilage; its content 
decreases considerably with cessation of growth (Glant et al., 1986). Degraded 
aggrecan molecules containing CS846 epitopes released from the matrix into the 
SF are detectable by immunoassay and indicative of aggrecan turnover (Frisbie 
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et al., 1999; Laverty et al., 2000; Thonar and Manicourt, 2001). This epitope re-
appears in adult cartilage in joints with osteochondritis dissecans (OCD) and is 
believed to get elevated in an attempt at repair (Frisbie et al., 1999). Increases in 
CS846 epitope in synovial fluid (SF) are seen after injury but this epitope also 
reappears in cartilage in the largest aggrecan molecules in the presence of os-
teoarthritis (OA) (Rikzalla el al., 1992; Lohmander et al., 1999). In OA, CS846 
epitope concentrations in cartilage correlate with those in SF. Thus, increases of 
the CS846 epitope in cartilage and SF suggest an increase in aggrecan synthesis 
(Laverty et al., 2000). 
Type II collagen is the principal triple helical collagen of articular carti-
lage. The degradation of mature type II collagen fibrils is collagenase dependent. 
The product of the primary initiating event of this cleavage can be measured by 
immunoassay of a C1,2C neoepitope (Billinghurst et al., 1997; Poole et al., 2003; 
Celeste et al., 2005). This assay detects not only the cleavage of type II collagen 
but also that of type I collagen present in the synovium, joint capsule, and liga-
ments (Billinghurst et al., 1997; Celeste et al., 2005). The levels of C1,2C in, and 
its release from, cartilage is increased in OA (Billinghurst et al., 1997). 
Substance P is a bioactive 11-amino-acid oligopeptide mediator that is re-
leased into SF from articular-type C nerve fibres in response to mechanical or 
chemical stimulation (Levine and Taiwo, 1989; Caron et al., 1992). Nerve fibres 
containing substance P have been demonstrated in the equine synovial membrane 
and subchondral bone, and multiple studies have identified elevated synovial 
fluid concentrations of substance P in arthritic equine joints as compared to nor-
mal ones (Caron et al., 1992; Nixon and Cummings, 1994; Fortier and Nixon, 
1997; Kirker-Head et al., 2000). Substance P is associated with clinically detect-
able joint pain in the horse (de Grauw et al., 2006). 
Several methods have been described in the equine literature to evaluate 
outcome measures of different articular resurfacing techniques, including post-
operative clinical assessment, long-term follow-up with owner questionnaires, 
radiological follow-up of the affected joints, follow-up arthroscopies, and ante- 
or postmortem histological evaluation of the transplanted area (Kold and Hick-
man, 1984; Howard et al., 1995; Bodó et al., 2000; Jackson et al., 2000; Hurtig et 
al., 2001; Sandler et al., 2002; Bodó et al., 2004; Wallis et al., 2008; Janicek et 
al., 2010; Nixon et al., 2011; Ortved et al., 2011; Malda et al., 2012; Bodó et al., 
2014; Santschi et al., 2015). However, to the best of the authors’ knowledge, no 
data are available on the evaluation of synovial biomarkers and basic parameters 
following AOT in humans or horses. 
The objective of this study was to explore donor (FP), recipient (MFC) 
and sham-operated joints in order to gain more information about postoperative 
processes following MP in the equine stifle joint. Our hypothesis was that syno-
vial parameters would show significant differences at different time points after 
the surgery (at days 3, 14, 60 and 180) compared to baseline level (day 0). 
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Materials and methods 
Experimental animals 
Nine skeletally mature warmblood horses (two stallions, one mare and six 
geldings), with an age range of 3 to 10 years (mean ± SD: 6.55 ± 2.3) and no his-
tory of orthopaedic disease, were enrolled in the study. Prior to enrolment the 
horses underwent a detailed lameness examination and radiological evaluation of 
the stifles. In full compliance with the Act on Animal Experiments, this study 
was evaluated and approved by the Ethics Committee of the Pest County Bureau 
for Animal Health. 
Surgical procedure and experimental design 
Antibiotics (amoxicillin trihydrate 5.6 mg/kg and potassium clavulanate 
1.4 mg/kg, Noroclav Inj., Norbook Ltd.) im. and 2.2 mg/kg phenylbutazone iv. 
were given to the horses prior to surgery. 
Both stifle joints of the nine horses were randomly assigned to either a 
transplanted (n = 14) or a sham (n = 4) group. The medial femoral trochlea was 
used as donor site in the transplanted group. Two cylindrical osteochondral grafts 
(8.5 mm in diameter and 25–30 mm in length) were harvested under arthroscopic 
guidance using the arthroscopic approach described previously (Bodó et al., 
2014). The same limb was flexed after the harvesting procedure. Transplantation 
into the MFC was carried out by conventional arthrotomy (Bodó et al., 2014). 
One graft, 20 mm in length, was transplanted into the weight-bearing surface of 
the MFC. Closure of the surgical wound was performed in four layers. Mo-
saicplasty instrumentation adapted to equine joints was provided by Metrimed 
Ltd. (Hódmezővásárhely, Hungary).  
Arthroscopic evaluation as well as mini-arthrotomy (1 cm in length) for 
the tubular chisel were performed for the sham-operated FP joints without har-
vesting the grafts. For the sham-operated recipient joints the same arthrotomic 
wound was created as during AOT, the MFC was visualised, and the wound was 
closed in four layers. All surgeries were performed by the same surgeon (GB). 
Postoperative care 
Horses were box-rested for 3 weeks followed by a 5- to 10-min/day hand 
walk for further eight weeks. After this 11-week postoperative period they were 
turned out in small paddocks. Oral phenylbutazone (1.1 mg/kg once daily) was 
administered for 4–7 days after the operation. For each horse, clinical examina-
tions were performed prior to day 0 and then throughout the study period. Radio-
graphs were taken six months after the surgeries. 
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Collection of synovial fluid 
Samples were collected from the FP and MFT joints before surgery (day 0) 
and on days 3, 14, 60 and 180 postoperatively. Three ml of SF were transferred 
in EDTA tubes for macroscopic evaluation, white blood cell (WBC) count and 
total protein measurements, while the remainder was centrifuged in serum tubes 
at 13,000 rpm for 15 min, aliquoted and stored at –80 °C until further analysis. 
Biomarker assays 
Substance P was measured using a commercial enzyme immunoassay kit 
(Cayman Chemical, Ann Arbor, MI, USA). The concentrations of C1,2C and 
CS846 epitopes were measured using competitive ELISA kits (IBEX, Montreal, 
Québec, Canada). A plate reader (BioTek 8000LX, Biotek Inc., USA) was used 
to measure the optical density (OD). The OD of substance P was measured at 
405 nm while that of epitopes C1,2C and CS846 at 450 nm. Specimens were 
measured in duplicate and the mean OD was used to determine the concentration 
after creation of the standard curve for each plate. The concentration was ex-
pressed as pg/ml (substance P), μg/ml (C1,2C), and ng/ml (CS846). All assays 
had been previously validated for use with equine SF (Frisbie et al., 1999; 
Celeste et al., 2005; de Grauw et al., 2006; Frisbie et al., 2008; Piat et al., 2012). 
The intra- and inter-assay coefficients of variation for the evaluation of these SF 
biomarkers were all < 5% or < 13%, respectively. 
Statistical analysis 
Statistical analysis was performed with a commercially available pro-
gramme (www.r-project.org). Distribution of the continuous data was tested with 
the Shapiro-Wilk test. Descriptive statistical results were expressed as mean ± 
SD. A two-way repeated-measures analysis of variance (ANOVA) was used to 
compare the main effects of the model including time (days 0, 3, 14, 60 and 180) 
and treatment (operated, sham). Post-hoc correction was used with the Bon-
ferroni method. Significance was set at P < 0.05. 
 
 
Results 
Clinical assessments 
All horses showed lameness of degree 2–3/5 [American Association of 
Equine Practitioners (AAEP) scores] in the immediate postoperative period. Joint 
effusion was also present in both (transplanted or sham-operated MFT and FP) 
joints, but it abated completely by the second month after surgery. The effusion 
did not disappear earlier in the sham-operated joints. 
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Lameness disappeared in all horses after two months except for one case 
where an MFT joint became infected after SF collection on day 14 and had to 
undergo multiple joint lavages and repeated arthroscopic evaluation. This horse 
showed lameness of 2/5 grade after 8 months. Proximal limb flexion tests were 
mildly positive for 5 out of the 18 stifles at two months after surgery and became 
negative four months postoperatively for all joints except the infected MFT joint, 
for which a mild positivity persisted throughout the study. The results of this 
joint were removed from all subsequent analyses. 
Radiographs were taken after the transplantation. Osteoarthritis was not 
identified in the stifles with radiographs except for the infected MFT joint, where 
a mild elongation was observed on the medial condyle of the tibia. 
Synovial fluid parameters 
The results of descriptive statistical data are presented in Tables 1 (FP joint) 
and 2 (MFT joint).  
White blood cell count (Tables 1 and 2, Fig. 1). The WBC count was sig-
nificantly increased in the operated FP joints on day 3 as compared with the 
sham FP or the operated MFT joints (Fig. 1). When compared with baseline val-
ues, all samples were significantly different at day 3. On days 14 and 60 signifi-
cant differences could be detected only in the sham MFT and operated MFT 
joints, respectively. 
Synovial total protein (TP) (Tables 1 and 2, Fig. 2). A significant increase 
in TP levels was observed in all joints on day 3 followed by a decline by day 14. 
The level of TP returned to normal by day 60 in all joints. No significant differ-
ences in TP levels were detected between sham and operated joints at any time 
point. 
Synovial biomarkers (Figs 3, 4 and 5). As compared to day 0 values, on 
days 3 and 14 there was a significant increase in substance P levels in all joints. 
No significant differences were observed between sham and operated joints at 
any time point (Fig. 3). As compared to day 0 values, on day 3 there was a sig-
nificant increase in C1,2C concentration in the operated joints and in the sham-
operated MFT joint, while the sham-operated FP joint did not show significant 
differences (Fig. 4). The concentration of CS846 biomarker significantly in-
creased on day 3 in the sham joints and in the operated MFT joint and signifi-
cantly decreased on day 14 in both types of MFT joints. No significant differ-
ences were observed in C1,2C and CS846 values between sham and operated 
joints at any time point (Figs 4 and 5). 
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Figs 1–5. Box plot white blood cell (WBC) count (Fig. 1), total protein concentration (Fig. 2) and 
concentrations of biomarkers Substance P (Fig. 3), C1,2C (Fig. 4) and CS846 (Fig. 5) in the synovial 
fluid of sham and operated femoropatellar (FP) and medial femorotibial (MFT) joints. Significant 
differences between the values of sham and operated joints at each time point are indicated by #. 
Significant differences between the values of operated MFT and operated FP joints at each time 
point are indicated by @. Significant differences between baseline and post-treatment values of op-
erated and sham joints are indicated by *. Differences at P < 0.05 were considered statistically sig-
nificant 
 
 
Discussion 
No significant differences were found between sham-operated joints and 
joints where harvesting or AOT was performed, except in WBC count at a single 
time point. This only significant difference between sham-operated FP joints and 
FP joints with graft harvest was found at day 3 and disappeared by day 14, when 
the WBC count returned to the baseline level. TP levels were elevated in all four 
types of joints (sham and operated FP and MFT) without any remarkable differ-
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ences between sham and operated groups. A potential cause of a higher peak in 
WBC count in the FP joints was the exposed subchondral bone, potentially pro-
viding WBCs with easy access to the FP joint from the exposed bone marrow 
spaces. All things considered, this might be a logical response compared to the 
MFT joints with a lower WBC count, where the drilled holes were sealed with 
transplanted osteochondral grafts.  
This finding correlates with a similar elevation of C1,2C biomarkers in the 
same sham-operated FP joints at day 3. C1,2C measures collagen type I and II 
degradation products, indicating cartilage degradation (type II collagen) and 
synovial inflammation (type I collagen) in the joint (Billinghurst et al., 1997; 
Celeste et al., 2005). This may be explained by the fact that these joint surfaces 
served as cartilage donors in the experiment and consequently sustained more 
tissue damage compared to the other joint types (operated FP and MFT and sham 
MFT), because the graft donor sites remained uncovered. An alternative cause of 
C1,2C rise could be the more pronounced synovial inflammation in the operated 
joints due to type I collagen degradation. However, the TP values, also markers 
of inflammation, did not corroborate these latter findings. Horses were kept in-
doors for up to 11 weeks in this study, in contrast to previous studies conducted 
by the same authors (Bodó et al., 2000, 2004, 2014), where they were let out into 
paddocks after three weeks. There is still a lack of evidence regarding the best 
time frame for keeping horses indoors with restricted exercise following AOT of 
the weight-bearing joint surface. It is known from previous studies that bony union 
of the transplanted grafts is complete after eight weeks following transplantation 
in dogs (Hangody et al., 1997). The data collected in this biomarker study sup-
port our hypothesis that the first two months seem to be critical also in horses to 
avoid any further contusion of the transplanted areas. Unfortunately, immediate 
weight-bearing cannot be avoided in the equine species. Although horses are turned 
out into paddocks, any quick turn, start or stop can induce further trauma to the 
transplanted grafts, which might influence integration and fusion of the transplants. 
Two major observations were made in this study. First, only subtle 
changes were noted in most of the SF inflammatory markers (WBC count, TP), 
all falling within the low inflammatory range (Steel, 2008). The highest concen-
tration of WBC count was 12 × 109 cells/l and the highest TP level was 4.5 g/dl 
on day 3. WBC count and TP level stayed under the septic limit during the re-
search except for one case where a MFT joint became infected after SF collec-
tion on day 14. Substance P reflects inflammation and pain (de Grauw et al., 
2006). This proved to be a sensitive marker in this study, staying on an elevated 
level after two weeks, and decreasing slowly to the normal level after two months. 
Its level remained similar in sham-operated and AOT joints, indicating that the 
trauma caused by AOT did not cause longer-acting pain compared to sham-
operated joints. TP values move together with the substance P parameters, be-
cause lower inflammation rate reduces the pain in the joint. Second, all of the 
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markers showed only temporary changes and returned to normal after a period of 
two weeks to 2–3 months. The markers remained at the baseline level after six 
months following AOT, indicating that no signs of osteoarthritic changes were 
detected in the equine stifle with biomarkers as well as with radiographs six months 
postoperatively. No evidence of increased collagen degradation was identified in 
the synovial fluid at 180 days based on C1,2C. In this study, no such changes 
were detected within six months after transplantation in the FP and MFT joints. 
Alterations of the synovial indices in this study were surprisingly subtle, 
although differences in the synovial WBC count and TP concentrations could be 
still detected compared to baseline samples. This is a favourable finding, as it in-
dicates that this surgery can be done with an acceptable level of discomfort even 
when it is performed parallel on both hindlimbs, and no osteoarthritic changes 
were detected in a six-month postoperative period. 
This study had several limitations. It is known that the FP and MFT syno-
vial cavities can communicate in 60–80% of cases. This means that metabolic 
changes reflected by synovial parameters in the FP joint will probably be similar 
those in the MFT joint. It is hard to determine whether changes are due altera-
tions of the donor or the transplanted site. Although the majority of parameters 
have returned to baseline values, transplantation did not cause lasting changes of 
the synovial parameters in those joints. Another limitation is the relatively low 
number of samples.  
Taking samples at weekly intervals could have provided more information 
regarding the subtle changes found between the samples taken in this study. 
Frisbie et al. (2008) took synovial samples at weekly intervals and found that 
most of the influence caused by arthrocentesis disappeared after two weeks. On 
the other hand, taking samples with such frequency could have influenced the 
data and increased the incidence of iatrogenic (septic) inflammation. This study 
investigated only three biomarkers, which was due to the limited budget avail-
able to us. Investigating more biomarkers could have highlighted further proc-
esses occurring in the joint after AOT (Lotz et al., 2013). Horses were turned out 
into paddocks but did not have controlled exercise, which would have been bene-
ficial for testing the results of this transplantation method. Further follow-up 
studies are needed to obtain more information about AOT in the long term. 
The results of this study are consistent with the findings of previous studies 
in the equine stifle (Bodó et al., 2014) and show that this transplantation method 
is a safe technique when performed on the equine medial femoral condyle. We 
could not detect any signs of incipient osteoarthritic changes with the help of dif-
ferent SF biomarkers and basic synovial parameters during the six-month post-
operative period. Osteoarthritic changes were not detected on radiographs six 
months after the surgeries. In future studies it would be beneficial to perform 
MRI evaluations of the stifle in order to visualise osteoarthritis in a more sensi-
tive way. A three-month stall confinement with walk on hand after three weeks 
176 TUSKA et al. 
Acta Veterinaria Hungarica 64, 2016 
seems to be a safe postoperative period of restricted exercise for horses undergo-
ing such surgery. More exercise could also shed light on the durability of the re-
pair. The results are very encouraging at this six-month time period; however, 
further longer-term studies are needed as OA is known to be a slowly progress-
ing joint disease. 
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